The International Perinatal Stem Cell Society - IPSCS officially launched on Wednesday, May 7th, in San Francisco. Perinatal stem cells have the potential to treat degenerative diseases contributing to extend or improve the quality of life.
"The International Perinatal Stem Cell Society's Inaugural Meeting being held today in San Francisco is one of many steps we plan to take in order to realize the clinical potential of perinatal stem cells," Kyle J. Cetrulo, President of the International Perinatal Stem Cell Society - IPSCS (www.perinatalstemcells.com), said in San Francisco on Wednesday, May 7th, with regard to the official launch of the international association.
"Perinatal stem cells have advantageous properties of both adult stem cells and embryonic stem cells but without the ethical questions as 99% of all perinatal tissues are discarded at birth," Mr. Cetrulo explained. "They have the powerful potential to treat conditions, including chronic wound healing, burns, stroke, cerebral palsy, diabetes and a whole host of other debilitating disorders".
"I am very pleased because great hope for the future is in the air today. Placenta perinatal stem cells will introduce a real revolution in medicine, not just by treating terrible diseases, but also helping to fight the most inevitable of all processes: getting old".
With those words, Marco Reguzzoni, founder of Biocell Center, the first group in the world to develop a technology for the preservation of perinatal stem cells, commented from San Francisco on the launch of the International Perinatal Stem Cell Society, of which he is a founding member.
Perinatal stem cells have the potential to treat degenerative diseases in which tissues and organs increasingly deteriorate over time, contributing to extend or improve the quality of life.
Among the speakers to highlight the great potentials of perinatal stem cells during the Perinatal Stem Cell Society Forum, that took place on Wednesday, May 7th, in San Francisco, Professor Ornella Parolini, Director of E. Menni Reserach Center of Fondazione Poliambulanza in Brescia, spoke about stem cells derived from amniotic membrane and their application, among others, to treat cornea lesions. Another Italian speaker at the forum was Professor Paolo De Coppi, Pediatric Surgeon who divides his work between the Great Ormond Street Hospital for Children and the UCL Institute of Child Health in London and the University of Padua.
The International Perinatal Stem Cell Society counts four Italians, the largest group after the US scientists, among its founding members. They are two scientists and two entrepreneurs, in the forefront of perinatal stem cells: Professor Giuseppe Simoni, geneticist and one of the main experts in the world in chorionic villi; Professor Claudio Giorlandino, gynecologist, Chairman of the Italian Society of Prenatal Diagnosis and Director of Artemisia; Federico Maggi, founder and President of TOMA; and Marco Reguzzoni, CEO of Biocell Center.
Biocell Center Corporation - Press Office - New York
Erika Esposito: 9175280903; email@example.com
Biocell Center - Ufficio Stampa - Milano
Alessia Quiriconi: +39 3474831339; firstname.lastname@example.org